Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

and experience the next generation of RAS-targeted drugs. Set to unite 150+ key leaders in biopharma and academia in Boston, this year’s event has a strong focus in tackling emerging resistance ...